Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Cervical Cancer|SCCHN|Pancreatic Cancer|Esophageal SCC|Metastatic Castration-resistant Prostate Cancer|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|Epithelial Ovarian Cancer|Endometrial Cancer|Tissue Factor-Expressing Solid Tumors
Interventions: DRUG: XB002|DRUG: Nivolumab|DRUG: Bevacizumab
Sponsor: Exelixis